Clinical Trial Detail

NCT ID NCT01974258
Title Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

non-small cell lung carcinoma

melanoma

Advanced Solid Tumor

colorectal cancer

Therapies

Onartuzumab + Vemurafenib

Cobimetinib + Onartuzumab

Cobimetinib + Onartuzumab + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST